retatrutide type 2 diabetes More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Retatrutide Shows Promise in Treating

The patient experience on phentermine is also distinctly different from what people expect

After SELECT, the debate ended

Betsy Dovec, MD, FACS , says that it's reasonable to wonder if GLP-1 patches will hit the market soon

Originally developed for managing type 2 diabetes, these medications are now making headlines for their broader impact on weight, metabolic health and cardiovascular health

Notice the continued reference to both overweight and obesity, since referring only to obesity may contribute to overlooking the risks and therapeutic opportunities associated with overweight

Unlike current single (GLP-1) and dual (GLP-1/GIP) agonist compounds like Semaglutide and Tirzepatide , Retatrutide is a triple agonist compound targeting three hormone receptors instead of only one or two: GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) GCG (glucagon receptor) According to a landmark clinical trial published in the New England Journal of Medicine , Retatrutide demonstrated significant weight reduction, up to 30%, in participants over a 48-week period, highlighting its potential as a next-generation metabolic peptide